Under the agreement, the company will provide community oncology practices with better access to oral oncology drugs, clinical programs and adherence-enhancing medication management programs.
RainTree Oncology president and CEO Mike Martin said the company’s resources integrate with their physician centric, patient focused initiative to provide important data to community oncology practices, which will allow the customers to better support cancer care through analysis of cancer patient compliance, adherence and outcomes.
"Diplomat is not only one of the nation’s largest dispensers of many oral oncolytics, such as Revlimid and Zytiga, but also brings impressive oncology-specific programs and data collection capabilities," Martin added.
RainTree also provides technology tools to practice pharmacists to track both the prescribing and fulfillment of oral oncology medications in practices, as well as patient utilization of these drugs.